ViiV Healthcare and GSK’s Cabenuva in a Phase III study showed superior efficacy versus daily oral antiretroviral treatment in HIV patients with a history of difficulties in taking daily pills.
Tag Archive for: Cabenuva
Today the company lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.
British drugmaker GSK’s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.
The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc.’s Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.